These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38824765)

  • 21. Characterization of treatment resistant depression episodes in a cohort of patients from a US commercial claims database.
    Kubitz N; Mehra M; Potluri RC; Garg N; Cossrow N
    PLoS One; 2013; 8(10):e76882. PubMed ID: 24204694
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Using a machine learning approach to investigate factors associated with treatment-resistant depression among adults with chronic non-cancer pain conditions and major depressive disorder.
    Shah D; Zheng W; Allen L; Wei W; LeMasters T; Madhavan S; Sambamoorthi U
    Curr Med Res Opin; 2021 May; 37(5):847-859. PubMed ID: 33686881
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnosis of major depressive disorder based on changes in multiple plasma neurotransmitters: a targeted metabolomics study.
    Pan JX; Xia JJ; Deng FL; Liang WW; Wu J; Yin BM; Dong MX; Chen JJ; Ye F; Wang HY; Zheng P; Xie P
    Transl Psychiatry; 2018 Jul; 8(1):130. PubMed ID: 29991685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Prevalence and National Burden of Treatment-Resistant Depression and Major Depressive Disorder in the United States.
    Zhdanava M; Pilon D; Ghelerter I; Chow W; Joshi K; Lefebvre P; Sheehan JJ
    J Clin Psychiatry; 2021 Mar; 82(2):. PubMed ID: 33989464
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The burden and the challenge of treatment-resistant depression.
    Touloumis C
    Psychiatriki; 2021 Dec; 32(Supplement I):11-14. PubMed ID: 34990376
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Economic Burden of Treatment-Resistant Depression in Privately Insured U.S. Patients with Physical Conditions.
    Zhdanava M; Kuvadia H; Joshi K; Daly E; Pilon D; Rossi C; Morrison L; Lefebvre P; Nelson C
    J Manag Care Spec Pharm; 2020 Aug; 26(8):996-1007. PubMed ID: 32552362
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence and clinical profiles of comorbid anxiety in first episode and drug naïve patients with major depressive disorder.
    Yang W; Zhang G; Jia Q; Qian ZK; Yin G; Zhu X; Alnatour OI; Trinh TH; Wu HE; Lang X; Du X; Zhang X
    J Affect Disord; 2019 Oct; 257():200-206. PubMed ID: 31301624
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Classification of different therapeutic responses of major depressive disorder with multivariate pattern analysis method based on structural MR scans.
    Liu F; Guo W; Yu D; Gao Q; Gao K; Xue Z; Du H; Zhang J; Tan C; Liu Z; Zhao J; Chen H
    PLoS One; 2012; 7(7):e40968. PubMed ID: 22815880
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment patterns in patients with treatment-resistant depression in Danish patients with major depressive disorder.
    Gronemann FH; Petersen J; Alulis S; Jensen KJ; Riise J; Ankarfeldt MZ; Solem EJ; Bødker N; Osler M
    J Affect Disord; 2021 May; 287():204-213. PubMed ID: 33799039
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Burden of treatment-resistant depression in Medicare: A retrospective claims database analysis.
    Pilon D; Joshi K; Sheehan JJ; Zichlin ML; Zuckerman P; Lefebvre P; Greenberg PE
    PLoS One; 2019; 14(10):e0223255. PubMed ID: 31600244
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current treatments used in clinical practice for major depressive disorder and treatment resistant depression in England: A retrospective database study.
    Denee T; Kerr C; Ming T; Wood R; Tritton T; Middleton-Dalby C; Massey O; Desai M
    J Psychiatr Res; 2021 Jul; 139():172-178. PubMed ID: 34077893
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tryptophan-kynurenine and lipid related metabolites as blood biomarkers for first-episode drug-naïve patients with major depressive disorder: An exploratory pilot case-control study.
    Kuwano N; Kato TA; Setoyama D; Sato-Kasai M; Shimokawa N; Hayakawa K; Ohgidani M; Sagata N; Kubo H; Kishimoto J; Kang D; Kanba S
    J Affect Disord; 2018 Apr; 231():74-82. PubMed ID: 29454180
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characteristics of Real-world Commercially Insured Patients With Treatment-resistant Depression Initiated on Esketamine Nasal Spray or Conventional Therapies in the United States.
    Karkare S; Zhdanava M; Pilon D; Nash AI; Morrison L; Shah A; Lefebvre P; Joshi K
    Clin Ther; 2022 Nov; 44(11):1432-1448. PubMed ID: 36207167
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early improvement and response to antidepressant medications in adults with major depressive disorder. Meta-analysis and study of a sample with treatment-resistant depression.
    Olgiati P; Serretti A; Souery D; Dold M; Kasper S; Montgomery S; Zohar J; Mendlewicz J
    J Affect Disord; 2018 Feb; 227():777-786. PubMed ID: 29254066
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The potential predictors for treatment-resistance depression after selective serotonin reuptake inhibitors therapy in Han Chinese: A resting-state functional magnetic resonance imaging study.
    Li Y; Yin Y; Yu Y; Hu X; Liu X; Wu S
    Early Interv Psychiatry; 2024 Feb; ():. PubMed ID: 38320861
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gender differences in prevalence and clinical correlates of anxiety symptoms in first-episode and drug-naïve patients with major depressive disorder.
    Yang WQ; Qu M; Fang HL; Phan AT; Wu HE; Lang XE; Zhang XY
    Compr Psychiatry; 2021 Nov; 111():152275. PubMed ID: 34560368
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The economic impact of depression: resistance or severity?
    Fostick L; Silberman A; Beckman M; Spivak B; Amital D
    Eur Neuropsychopharmacol; 2010 Oct; 20(10):671-5. PubMed ID: 20624674
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The lack of association between components of metabolic syndrome and treatment resistance in depression.
    Sagud M; Mihaljevic-Peles A; Uzun S; Cusa BV; Kozumplik O; Kudlek-Mikulic S; Mustapic M; Barisic I; Muck-Seler D; Pivac N
    Psychopharmacology (Berl); 2013 Nov; 230(1):15-21. PubMed ID: 23579429
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of metabolomics-based urinary biomarker models for recognizing major depression disorder and bipolar disorder.
    Wang T; Yang J; Zhu Y; Niu N; Ding B; Wang P; Zhao H; Li N; Chao Y; Gao S; Dong X; Wang Z
    J Affect Disord; 2024 Jul; 356():1-12. PubMed ID: 38548210
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Difference in remission in a Chinese population with anxious versus nonanxious treatment-resistant depression: a report of OPERATION study.
    Wu Z; Chen J; Yuan C; Hong W; Peng D; Zhang C; Cao L; Fang Y
    J Affect Disord; 2013 Sep; 150(3):834-9. PubMed ID: 23570952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.